Literature DB >> 29955500

Drug-induced parkinsonism: A case report.

Brianna D Morabito1, Barbara Paulison2.   

Abstract

Drug-induced parkinsonism is defined as the appearance of parkinsonism on treatment with pharmaceutical agents. Symptoms typically manifest within a few days, and 90% of cases emerge within 3 months. The patient was a 68-year-old white man with a past psychiatric history significant for bipolar I versus cyclothymic disorder. The patient presented with pressured speech, flight of ideas, distractibility, delusions, and disorganized thinking. He was started on risperidone and, due to a subclinical response, was cross-tapered from risperidone to olanzapine, and divalproex was started. The patient was then given paliperidone 234 mg long-acting injection (LAI) and a second loading dose of 156 mg 1 week later. The patient's cognitive and functional status subsequently declined, all neuroleptics were discontinued, and he was diagnosed with drug-induced parkinsonism. After a complicated hospital course the patient died approximately 5 months after the administration of paliperidone LAI. Although there are several confounding factors, due to the temporal relationship of events it is likely that paliperidone LAI was a contributing factor for the development of severe parkinsonism. Practitioners should be cognizant of the potential long-term consequences of paliperidone LAI.

Entities:  

Keywords:  Invega Sustenna®; Parkinson disease; antipsychotic; divalproex; drug-induced parkinsonism; long-acting injection; paliperidone; parkinsonism

Year:  2018        PMID: 29955500      PMCID: PMC6007667          DOI: 10.9740/mhc.2017.03.065

Source DB:  PubMed          Journal:  Ment Health Clin        ISSN: 2168-9709


  7 in total

Review 1.  The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.

Authors:  Sofia Brissos; Miguel Ruiz Veguilla; David Taylor; Vicent Balanzá-Martinez
Journal:  Ther Adv Psychopharmacol       Date:  2014-10

2.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

Review 3.  Valproic acid-induced parkinsonism in the elderly: a comprehensive review of the literature.

Authors:  Fade Mahmoud; Rajesh R Tampi
Journal:  Am J Geriatr Pharmacother       Date:  2011-10-10

4.  Once-monthly paliperidone injection for the treatment of schizophrenia.

Authors:  Delia Bishara
Journal:  Neuropsychiatr Dis Treat       Date:  2010-09-07       Impact factor: 2.570

Review 5.  Dopamine transporter scanning in the evaluation of patients with suspected Parkinsonism: a case-based user's guide.

Authors:  Federico Rodriguez-Porcel; Sheheryar Jamali; Andrew P Duker; Alberto J Espay
Journal:  Expert Rev Neurother       Date:  2015-12-02       Impact factor: 4.618

6.  Dosing and switching of paliperidone ER in patients with schizophrenia: recommendations for clinical practice.

Authors:  Joseph Peuskens; Gabriel Rubio; Andreas Schreiner
Journal:  Ann Gen Psychiatry       Date:  2014-04-01       Impact factor: 3.455

7.  Neuroleptic-induced Parkinsonism: Clinicopathological study.

Authors:  Umar A Shuaib; Ali H Rajput; Christopher A Robinson; Alex Rajput
Journal:  Mov Disord       Date:  2015-12-11       Impact factor: 10.338

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.